Norway: Shaping the future of radiopharmaceuticals
17 April 2026, 17:30 - 19:30 GMT+01:00
Seminar
Norway is a fully integrated hub for radiopharmaceutical innovation, combining strong research, clinical capabilities and industrial-scale manufacturing. Join us at this networking reception to learn how science is translated into clinical practice and global markets.
This reception brings together representatives from across the Norwegian radiopharmaceutical ecosystem, supported by the Norwegian Research Council. You will meet stakeholders from research and academia and gain insight into Norway’s strong scientific environments and interdisciplinary expertise within nuclear medicine, chemistry and oncology. The event will also highlight Norway’s preclinical and clinical infrastructure, including how companies can engage with national capabilities and trial environments.
During the reception, the following topics will be highlighted:
- Presentation of Norway’s strengths in commercial production of radiopharmaceuticals
- Insights into national capabilities in handling and logistics within nuclear medicine
- How Norway offers an integrated value chain from research to manufacturing
- Closing remarks by Dimitrios Mantzilas, Actithera
- Informal networking with finger food and refreshments
Contact us
Contact our experts to discuss scientific and clinical progress in radiopharmaceuticals.
Signe Øien Fretland
Head of NorTrials coordinating unit; Cand. Pharm.
Monica Larsen
Senior Advisor, LMI
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.